REOLYSIN® is a formulation of human reovirus type 3 Dearing (T3D) which is being developed by Oncolytics Biotech Inc. for a number of cancer indications including pancreatic ductal adenocarcinoma (PDAC) (see here). It has entered clinical trials for pancreatic cancer in combination with a number of drugs including standard chemotherapeutics and newer immune checkpoint targeting antibodies (Pembrolizumab: trade name KEYTRUDA®) (See table 1).
ClinicalTrials.gov links
NCT02620423, NCT01280058, NCT00998322
Update of NCT01280058 (NCI-8601) trial based on data collected up to January 19, 2016 from the NCI
The overall survival rate was increased. A proportion of patients receiving REOLYSIN® were alive beyond three years, whereas no patients in the control group survived beyond one year.
Final results from Oncolytics Biotech Inc.’s NCT00998322 (REO 017) Phase II study
http://www.oncolyticsbiotech.com/wp-content/uploads/2015/07/panc-poster-June22-2015.pdf
Overall survival rates were increased and the immune checkpoint protein PD-L1 was demonstrated to be increased in post-treatment tumours. This formed a rationale for the use of Pembrolizumab (KEYTRUDA®) in the new NCT02620423 (REO 024) trial.
